MiMedx Group (MDXG) Offers FY18 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St set to open lower as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Goldman sees central bank demand providing a floor for gold prices
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
MiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 Million
December 13, 2017 7:00 AM ESTMARIETTA, Ga., Dec. 13, 2017 /PRNewswire/ --Â MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its guidance for full year 2018.
Full Year 2018 Guidance Highlights:The Company's full year 2018 expectations include:
Revenue estimated between $383 to $387 million Gross profit margins expected to be in the range of 89% to 90% Operating Income expected to be in... More